SCHEMBL463600

SCHEMBL463600

N#Cc1ccc(C(F)(F)F)cc1N

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 6/20 0.47
ALDH1A1 P00352 5/20 0.46
KDM4E B2RXH2 4/20 0.46
HSD17B10 Q99714 2/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
KIF11 P52732 2/20 0.42
TAS2R14 Q9NYV8 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
GFER P55789 1/20 0.42
CFTR P13569 1/20 0.41
ALOX15 P16050 1/20 0.41
BRCA1 P38398 1/20 0.41
ALOX5AP P20292 1/20 0.41
FEN1 P39748 1/20 0.41
TSHR P16473 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6780932 0.85 KIF11 (0.55) ARALDH1A1KDM4EHSD17B10KIF11
SCHEMBL29646422 0.84 ALOX5AP (0.44) ARALDH1A1KDM4EHSD17B10PKM
SCHEMBL165877 0.84 ALOX5AP (0.44) ARALDH1A1KDM4EHSD17B10PKM
SCHEMBL24749621 0.81 AR (0.52) ARL3MBTL1MAPTRAB9ALMNA
SCHEMBL30768289 0.81 AR (0.52) ARL3MBTL1MAPTRAB9ALMNA
SCHEMBL29546917 0.81 AR (0.52) ARKIF11TAS2R14CYP11B1CYP11B2
SCHEMBL12151755 0.81 AR (0.52) ARKIF11TAS2R14CYP11B1CYP11B2
SCHEMBL8969267 0.80 ALDH1A1 (0.52) ARALDH1A1KDM4EHSD17B10PKM
SCHEMBL17782865 0.78 AR (0.49) ARKIF11TAS2R14CYP11B1CYP11B2
SCHEMBL495426 0.78 CYP11B1 (0.57) ARKIF11TAS2R14ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106946800-A A kind of synthetic method of (1H, the 3H) diketone of quinazoline 2,4 and its derivative 华东师范大学 2017-07-14 CN claimed
CN-101565369-B Method for preparing 3-bromine-5-trifluoromethylbenzoic acid JIANGSU KAIYUAN PHARMACEUTICAL CHEMICAL ENGINEERING CO LTD 2012-10-03 CN claimed
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND SHOUYAO HOLDINGS BEIJING CO LTD (CN) 2025-07-10 US disclosed
WO-2025085233-A1 NOVEL DERIVATIVES OF QUINOLINONES, AND COMPOSITIONS AND METHODS THEREOF ENSEM THERAPEUTICS, INC. (US) 2025-04-24 WO disclosed
US-12257243-B2 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage NOVARTIS AG (CH) 2025-03-25 US disclosed
EP-4501912-A1 NOVEL HETEROCYCLIC COMPOUND Shouyao Holdings (Beijing) Co., Ltd. (CN) 2025-02-05 EP disclosed
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
CN-118475560-A Novel heterocyclic compound 首药控股(北京)股份有限公司 2024-08-09 CN disclosed
CN-118324761-A USP inhibitor, preparation method and application thereof 北京华森英诺生物科技有限公司 2024-07-12 CN disclosed
CN-113015735-B 5-Hydroxy-7-oxabicyclo [2.2.1] heptane-2-carboxamide derivatives for inducing chondrogenesis for the treatment of joint damage 诺华股份有限公司 2024-06-21 CN disclosed
CN-118108627-A Hydrogenation method for breaking fluorocarbon bonds of trifluoromethyl aromatic hydrocarbon 中国科学院大连化学物理研究所 2024-05-31 CN disclosed
US-5037833-A Anticholinergic agents; alzheimer's disease HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1991-08-06 US disclosed
US-5002955-A Pyrroloquinolines for enhancement of memory HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) 1991-03-26 US disclosed
US-4843079-A ALZHEIMER*S DISEASE HOECHST-ROUSSEL PHARMACEUTICALS, INC. (US) 1989-06-27 US disclosed
EP-0306826-A1 N-(substituted alkylidene)fused bicycloalkylidene and hetero-alkylidene quinolinamines, a process for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1989-03-15 EP disclosed
EP-0287977-A2 Fused heteroalkylene quinolinamines, a process and intermediates for their preparation and their use as medicaments HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) 1988-10-26 EP disclosed
EP-0280156-A2 Process for the preparation of acetoacetylarylamides-heteroarylamides respectively of deactived aromatic compounds HOECHST AKTIENGESELLSCHAFT (DE) 1988-08-31 EP disclosed
US-3987192-A ANTIALLERGENS AND ANTIANAPHYLAXID; 2'-CYANO-OXANILIC ACID THE UPJOHN COMPANY (US) 1976-10-19 US disclosed
US-RE28939-E MUSCLE RELAXANTS, ANALGESICS SMITHKLINE CORPORATION (US) 1976-08-24 US disclosed
US-3976633-A ANORECTIC, ANTIOBESITY SMITHKLINE CORPORATION (US) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250221979-A1 NOVEL HETEROCYCLIC COMPOUND MAPT, MNAT1, MAT2A AR 1962/4885ALDH1A1 996/4885KDM4E 3698/4885
US-12257243-B2 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage COL2A1, COL1A1, FGF1 AR 1318/4885ALDH1A1 8/4885KDM4E 1556/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.